PALIRODEN

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H24F3N
Molecular Weight	407.4707
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C1=CC(=CC=C1)C2=CCN(CCC3=CC=C(C=C3)C4=CC=CC=C4)CC2

InChI

InChIKey=CNEWKIDCGDXBDE-UHFFFAOYSA-N

InChI=1S/C26H24F3N/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21/h1-12,14,19H,13,15-18H2

HIDE SMILES / InChI

Molecular Formula	C26H24F3N
Molecular Weight	407.4707
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800013042 | https://www.ncbi.nlm.nih.gov/pubmed/16472201 | https://clinicaltrials.gov/ct2/show/NCT00220272 | https://clinicaltrials.gov/ct2/show/NCT00285025 | https://www.thepharmaletter.com/article/sanofi-aventis-to-file-31-ndas-by-end-2010-with-10-likely-blockbuster-drugs

Paliroden is an orally active drug that activates the synthesis of endogenous neurotrophins or nerve growth factors. Paliroden was investigated in phase II clinical trial in patients with Alzheimer's disease and to evaluate its effect on 18F-Dopa PET imaging in patients with Parkinson's disease. The further development of paliroden was discontinued due to its insufficient efficacy.

Originator

Approval Year

PubMed

Title	Date	PubMed
Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis.	2006-02	16472201

Sample Use Guides

In Vivo Use Guide

The primary objective is to study the effect of SR57667B (PALIRODEN) at the dose of 4 mg/d on progression of dopaminergic nigro-striatal lesions assessed by 18F-Dopa PET imaging.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:30:35 GMT 2025` Edited by `admin` on `Mon Mar 31 18:30:35 GMT 2025`
Record UNII	17VJ76L90T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SR5-7667B

Preferred Name

English

PALIRODEN

Official Name

English

paliroden [INN]

Common Name

English

SR57667 BASE

Code

English

SR57667B

Code

English

1-(2-(BIPHENYL-4-YL)ETHYL)-4-(3-(TRIFLUOROMETHYL)PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509

Created by admin on Mon Mar 31 18:30:35 GMT 2025 , Edited by admin on Mon Mar 31 18:30:35 GMT 2025

Code System Code Type Description

ChEMBL

CHEMBL2107767

Created by admin on Mon Mar 31 18:30:35 GMT 2025 , Edited by admin on Mon Mar 31 18:30:35 GMT 2025

PRIMARY

DRUG BANK

DB05454

Created by admin on Mon Mar 31 18:30:36 GMT 2025 , Edited by admin on Mon Mar 31 18:30:36 GMT 2025

PRIMARY

SMS_ID

300000034324

Created by admin on Mon Mar 31 18:30:36 GMT 2025 , Edited by admin on Mon Mar 31 18:30:36 GMT 2025

PRIMARY

INN

8638

Created by admin on Mon Mar 31 18:30:35 GMT 2025 , Edited by admin on Mon Mar 31 18:30:35 GMT 2025

PRIMARY

FDA UNII

17VJ76L90T

Created by admin on Mon Mar 31 18:30:36 GMT 2025 , Edited by admin on Mon Mar 31 18:30:36 GMT 2025

PRIMARY

CAS

188396-77-2

Created by admin on Mon Mar 31 18:30:35 GMT 2025 , Edited by admin on Mon Mar 31 18:30:35 GMT 2025

PRIMARY

PUBCHEM

11567682

Created by admin on Mon Mar 31 18:30:35 GMT 2025 , Edited by admin on Mon Mar 31 18:30:35 GMT 2025

PRIMARY

NCI_THESAURUS

C82298

Created by admin on Mon Mar 31 18:30:35 GMT 2025 , Edited by admin on Mon Mar 31 18:30:35 GMT 2025

PRIMARY

EPA CompTox

DTXSID60870180

Created by admin on Mon Mar 31 18:30:36 GMT 2025 , Edited by admin on Mon Mar 31 18:30:36 GMT 2025

PRIMARY

Related Record Type Details


					34PAS3CUV2

PALIRODEN FUMARATE

SALT/SOLVATE -> PARENT

Amount:


					V7FWP1D62O

NERVE GROWTH FACTOR

TARGET->ACTIVATOR OF EXPRESSION

Amount:

Related Record Type Details


					17VJ76L90T

PALIRODEN

ACTIVE MOIETY

Comments:

activates the synthesis of endogenous neurotrophins

Amount: